RxDoctor Payments Data

Arpan Bhakta, MD

Internal Medicine · Southgate, MINPI 1598822520

Payments from drug & device makers

$573in general payments, 2019–2025

Across 35 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$136
  • Pfizer$123
  • Novo Nordisk$103
  • AstraZeneca$70
  • Abbott$43
  • Lilly USA, LLC$31
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK9$136
Pfizer7$123
Novo Nordisk6$103
AstraZeneca4$70
Abbott3$43
Lilly USA, LLC2$31
Merck1$24
Exact Sciences1$16
AbbVie1$14
Novartis1$13

How this compares

$573 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$86,757
Medicare patients
159
Services billed
1,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$134,601
JanuviaSitagliptin Phosphate52$68,595
JardianceEmpagliflozin48$59,985
TrulicityDulaglutide31$55,146
EntrestoSacubitril/Valsartan30$49,796
XareltoRivaroxaban41$42,560
MounjaroTirzepatide23$32,597
Tresiba Flextouch U-200Insulin Degludec17$26,272
RybelsusSemaglutide13$24,380
OzempicSemaglutide14$20,418
Mesalamine20$14,825
PaxlovidNirmatrelvir/Ritonavir21$11,940
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen599$8,560
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$8,355
Atorvastatin Calcium556$7,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$123$146,540154 claims
Lilly USA, LLCTrulicity, Mounjaro$31$87,74354 claims
MerckJanuvia$24$68,59552 claims
NovartisEntresto$13$49,79630 claims
Novo NordiskRybelsus, Ozempic$103$44,79827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southgate

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →